119 related articles for article (PubMed ID: 22234090)
1. The prognostic impact of O6-methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: a clinicopathologic and immunohistochemical study of seven cases at a single institution.
Lin JW; Wu YT; Chang IW
Indian J Pathol Microbiol; 2011; 54(4):683-7. PubMed ID: 22234090
[TBL] [Abstract][Full Text] [Related]
2. Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.
Araki Y; Mizoguchi M; Yoshimoto K; Shono T; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
Brain Tumor Pathol; 2011 Feb; 28(1):25-31. PubMed ID: 21249460
[TBL] [Abstract][Full Text] [Related]
3. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
6. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of P53, O6-methylguanine-dna methyltransferase and epidermal growth factor receptor in glioma.
Fu XR; Sun ZC; Chang Y
J Biol Regul Homeost Agents; 2015; 29(4):853-8. PubMed ID: 26753647
[TBL] [Abstract][Full Text] [Related]
8. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
[TBL] [Abstract][Full Text] [Related]
9. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
Kang SH; Park KJ; Kim CY; Yu MO; Park CK; Park SH; Chung YG
J Neurooncol; 2011 Feb; 101(3):477-86. PubMed ID: 20556478
[TBL] [Abstract][Full Text] [Related]
10. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
11. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
12. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of O6-methylguanine-DNA methyltransferase by immunohistochemistry: best clinical and research practices.
Neto JC; Carvalho K; Olivieri E; Carraro D; Cunha I; Vassallo J; Kagohara L; Soares F; Rocha R
Pathol Res Pract; 2011 Aug; 207(8):492-7. PubMed ID: 21767920
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
[No Abstract] [Full Text] [Related]
15. Clinicopathologic and genomic features of gliosarcomas.
Lee D; Kang SY; Suh YL; Jeong JY; Lee JI; Nam DH
J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
[TBL] [Abstract][Full Text] [Related]
16. MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience.
Schlosser S; Wagner S; Mühlisch J; Hasselblatt M; Gerss J; Wolff JE; Frühwald MC
Pediatr Blood Cancer; 2010 Feb; 54(2):228-37. PubMed ID: 19856394
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study.
Chang IW; Hsu CT; Lin JW; Hung CH
Folia Neuropathol; 2013; 51(4):275-82. PubMed ID: 24374955
[TBL] [Abstract][Full Text] [Related]
18. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
[TBL] [Abstract][Full Text] [Related]
19. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
[TBL] [Abstract][Full Text] [Related]
20. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
